Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:        
Contract Revenue $ 1,063 $ 1,096 $ 2,125
Costs and expenses:        
Research and development 3,295 3,707 10,824 12,811
General and administrative 2,839 2,818 8,151 8,424
Total costs and expenses 6,134 6,525 18,975 21,235
Loss from operations (6,134) (5,462) (17,879) (19,110)
Sale of New Jersey net operating losses & tax credits 1,734
Other income, net 79 251 13
Net loss $ (6,055) $ (5,462) $ (17,628) $ (17,363)
Net loss per share - basic $ (0.03) $ (0.03) $ (0.08) $ (0.08)
Net loss per share - diluted $ (0.03) $ (0.03) $ (0.08) $ (0.08)
Weighted average common shares outstanding:        
Weighted average common shares outstanding - basic 217,264,526 216,864,526 217,264,526 216,792,083
Weighted average common shares outstanding - diluted 217,264,526 216,864,526 217,264,526 216,792,083
Other comprehensive gain/(loss), net of tax        
Unrealized gain/(loss) on securities available-for-sale $ 155 $ (181) $ 465 $ (790)
Other comprehensive gain/(loss), net of tax 155 (181) 465 (790)
Comprehensive loss $ (5,900) $ (5,643) $ (17,163) $ (18,153)